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One Sentence Summary: Development of NASH fibrosis is accompanied by 16	
accumulation of hepatic eosinophils and driven by TGF-b and profibrotic type 2 17	
inflammation. 18	
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Abstract 28	
Non-alcoholic fatty liver disease (NAFLD) is now the most common progressive 29	
liver disease in developed countries and is the second leading indication for liver 30	
transplantation due to the extensive fibrosis it causes. NAFLD progression is 31	
thought to be tied to chronic low-level type-1 inflammation originating in the 32	
adipose tissue during obesity, however the specific immunological mechanisms 33	
regulating progression of NAFLD-associated fibrosis in the liver are unclear. To 34	
investigate the immunopathogenesis of NAFLD more completely, we investigated 35	
adipose dysfunction, steatohepatitis (NASH), and fibrosis in mice that develop 36	
polarized type-1 or type-2 immune responses. Unexpectedly, obese IL-10/IL-4 37	
deficient mice (type-1 polarized) were highly resistant to NASH. This protection 38	
was associated with an increased hepatic IFN-γ signature. Conversely, IFN-γ 39	
deficient mice progressed rapidly to NASH with evidence of fibrosis dependent 40	
on TGF-β and IL-13 signaling. Unlike increasing type-1 inflammation and the 41	
marked loss of eosinophils seen in expanding adipose tissue, progression of 42	
NASH was associated with increasing eosinophilic type-2 liver inflammation in 43	
mice and human patient biopsies. Finally, simultaneous inhibition of TGF-b and 44	
IL-13 signaling attenuated the fibrotic machinery more completely  than TGF-45	
b alone in NAFLD-associated fibrosis. Thus, although type-2 immunity maintains 46	
healthy metabolic signaling in adipose tissues, it exacerbates the progression of 47	
NAFLD collaboratively with TGF-b in the liver.  48	
 49	
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INTRODUCTION 52	
Treating the individual sequelae of the metabolic syndrome associated with 53	
obesity and type II diabetes represents one way to alleviate the overall burden of 54	
disease. For example, the hepatic manifestation of metabolic syndrome, non-55	
alcoholic fatty liver disease (NAFLD), is now the most common form of chronic 56	
liver disease , is growing in prevalence, and will soon be the most common 57	
cause of liver transplantation in the United States (1-3). This is highlighted by a 58	
recent estimate that NAFLD affects 64 million people in the US, with annual 59	
direct medical costs projected at 103 billion dollars (4). Although a great deal of 60	
research has focused on obesity, metabolic alterations in disease, adipose tissue 61	
dysregulation, and the pathophysiology of NAFLD, the molecular and 62	
immunological mechanisms that facilitate the progression of NAFLD to non-63	
alcoholic steatohepatitis (NASH) and cirrhosis remain much less clear (5). As 64	
severe cirrhosis is the ultimate reason patients require liver transplant and the 65	
presence of fibrosis has been identified as the best predictor of clinical outcome 66	
and mortality (6, 7), a better understanding of the mechanisms that drive 67	
fibrogenesis in NAFLD could reveal novel treatment strategies and have a major 68	
impact on morbidity and mortality. However, progress in this area has been 69	
stymied by the absence of preclinical models that reliably reproduce 70	
inflammatory and fibrotic components seen in human disease (8, 9).  71	
 72	
It is clear that the initiation and progression of NAFLD along its spectrum of 73	
severity is intricately associated with the inflammatory processes that are driven 74	
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by chronic obesity. The initiation of dyslipidemia and lipogenesis in the liver is 75	
tied to insulin resistance and underlying adipose tissue inflammation. How the 76	
dysregulated immune response in the adipose tissue affects whole organism 77	
metabolism during homeostasis and obesity has been the topic of intense study. 78	
The emerging model suggests that homeostatic type-2 immunity in adipose 79	
tissues driven by IL-5, IL-4, and IL-13 production from innate type-2 lymphocytes 80	
(ILC2s), resident eosinophils, regulatory T cells and alternatively activated 81	
macrophages maintains healthy metabolic signaling (10-15). During obesity this 82	
set point is skewed towards type-1 inflammation with increasing production of IL-83	
1β, TNF-α, IL-6, IL-12, and IFN-γ, resulting in loss of local and then systemic 84	
insulin sensitivity and establishment of the chronic low level type-1 inflammation 85	
that is the hallmark of the metabolic syndrome. Thus, prevailing models hold that 86	
the inflammation contributing to NASH, cirrhosis, and eventual liver failure is an 87	
extension of dysregulated adipose tissue inflammation (16).  88	
 89	
In the present study, we investigated whether the type-1 inflammatory response 90	
in obese mice directly contributes to the development NAFLD. Using a variety of 91	
transgenic mice that develop highly polarized type-1 and type-2 immune 92	
responses, we examined whether the progression of high fat diet induced NASH 93	
and fibrosis is influenced by changes in type-2 immunity. Surprisingly, our studies 94	
reveal a disconnect in how obesity and the loss of type-2 effector function in 95	
adipose tissues impacts the progression of inflammation, NASH, and fibrosis in 96	
the liver. Indeed, in contrast to its protective role in metabolism, adipose tissue 97	
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homeostasis, and obesity, we show that the type-2 cytokine IL-13 collaborates 98	
with TGF-b to drive liver fibrogenesis in HFD-induced obesity.   99	
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Results 121	
NASH and fibrosis develop late in mice fed a high fat diet 122	
NASH and the accompanying development of hepatic fibrosis are complications 123	
linked to chronic obesity. To establish a timeline for the development of NASH 124	
and to determine the time point at which obese mice develop NASH with fibrosis, 125	
we subjected animals to a high fat diet (HFD) for 15 and 40 weeks and then 126	
examined them for the hallmark features of steatohepatitis. Mice on HFD for 15 127	
weeks gained appreciable weight and developed hepatomegaly (Fig. 1A). 128	
Despite being steatotic, there was no detectable inflammation, hepatocyte 129	
damage at this early time point, as assessed by liver leukocyte numbers (Fig. 130	
1B), serum aminotransferase level (Fig. 1C).  Oil red O staining was modest at 131	
this time point compared with 40 weeks (Fig. 1D). We also did not detect staining 132	
for ballooning hepatocytes (Fig. 1E), or fibrosis by picrosirius red staining of liver 133	
sections (Fig. 1F, top panel). Nevertheless, after 40 weeks, mice on HFD 134	
displayed increases in leukocyte infiltration of the liver (Fig. 1B), with histological 135	
evidence of marked lobular inflammation (Fig. 1E, inset). Additionally, increases 136	
in aminotransferases in serum (Fig. 1C) suggested that chronic HFD led to 137	
substantial hepatocellular damage. This was characterized by hepatocellular 138	
macrosteatosis (Fig. 1D) and ballooning degeneration, identified through 139	
immunohistochemical and immunofluorescent staining for ubiquitin and hepatic 140	
loss of keratin 8/18 staining (Fig. 1E and supplemental Fig. 1A). There was also 141	
significant pericellular zone 3 accumulation of collagen in the livers of mice fed a 142	
HFD (Fig. 1F, lower panel), and increased expression (supplemental Fig. 1B) 143	
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and immunofluorescent staining for smooth muscle actin (supplemental Fig. 1C), 144	
which are defining features of NASH. This timeline is in agreement with 145	
previously published work which reports NASH phenotypes present in wild-type 146	
mice on a HFD by 34 weeks (17). As predicted, the NASH phenotype was 147	
accompanied by increases in adipose inflammation measured by histological 148	
immune infiltration (Fig. 1G), presence of crown-like structures (Fig. 1G, 149	
arrowheads) and increased TNF-α expression (Fig. 1H). Furthermore, the 150	
increased inflammation in adipose tissues was accompanied by a loss of 151	
eosinophils as has been previously reported (Fig. 1I)(15). The increased 152	
inflammation in adipose tissue did result in increased TGF-β expression and 153	
induction of a number of collagens and metalloproteinases, however we did not 154	
detect development of substantial fibrosis by picrosirius red staining of adipose 155	
tissue at either time point (Supplemental Fig. 2). These studies demonstrate that 156	
obese mice are susceptible to the sequelae of NAFLD, but only when chronically 157	
exposed to a HFD. These data also support the model that progression of 158	
NAFLD in obesity is associated with a loss of type-2 homeostatic set points and 159	
expansion of inflammation in adipose tissues. 160	
  161	
Type-1 immunity drives metabolic disease but regulates progression of 162	
NAFLD  163	
To determine whether the dysregulated pro-inflammatory immune response in 164	
adipose tissues of obese mice contributes to the development and progression of 165	
NAFLD, we investigated whether primary drivers of type-2 immunity protect 166	
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against NAFLD. We utilized IL-4-/- and double IL-10-/-/IL-4-/- mice, which were 167	
previously shown to develop increasingly polarized type-1 inflammation following 168	
sterile or infectious challenge (18, 19).	Our goal with the IL-10-/-/IL-4-/- mice was 169	
to assess extreme type-1 inflammatory skewing rather than the specific 170	
contribution of IL-10 to NAFLD, which remains unclear despite being previously 171	
studied (20-25). The single IL-10-/- mice, in contrast to the IL-10-/-/IL-4-/- mice, 172	
develop more of a mixed Th1/Th2 response when challenged with various 173	
inflammatory stimuli, which may in part explain the contradictory results 174	
regarding IL-10 in NAFLD (18, 19). Indeed, we observed consistently low and 175	
unchanging levels of IL-10 with disease in mice and in human microarray data 176	
(Supplemental Fig. 3). Thus, we hypothesized that the IL-4-/- and IL-10-/-/IL-4-/- 177	
genetically deficient mice would display a progressive worsening of metabolic 178	
homeostasis, obesity, adipose tissue dysregulation, and increased progression 179	
towards NASH and fibrosis because of their highly-polarized type-1 inflammatory 180	
response.  181	
 182	
When challenged with a HFD for 15 weeks, IL-4-/- mice developed similar obesity 183	
as wild type mice measured by body composition (Fig. 2A) and serum leptin 184	
levels (Fig. 2B). However, the IL-4-/- mice displayed slightly worse hepatomegaly 185	
(Fig. 2C), despite having similar liver triglycerides (Fig. 2D). Unexpectedly, IL-10-186	
/-/IL-4-/- mice were significantly protected from hepatomegaly, increased serum 187	
aminotransferases, and their liver triglyceride content and steatosis was 188	
markedly reduced relative to WT and IL-4-/- mice (Fig. 2C, D and E). This was 189	
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surprising because the IL-10-/-/IL-4-/- mice were similarly susceptible to obesity 190	
compared to wild type mice as measured by body composition and serum leptin 191	
levels (Fig. 2A and B). This protection from the features of NAFLD despite 192	
normal susceptibility to obesity was sustained as long as 40 weeks on the HFD in 193	
the IL-10-/-/IL-4-/- mice (Supplemental Fig. 4). Perigonadal adipose tissues were 194	
also analyzed for evidence of dysregulated pro-inflammatory mediator 195	
expression. All three groups showed marked increases in tnf and ccl2, as well as 196	
readily observable increases in histological adipose immune infiltration and 197	
abundant presence of crown-like structures when fed a HFD (Fig. 2F and G.). 198	
The switch towards type-1 inflammation in adipose tissues was also 199	
accompanied by a substantial reduction in the number of adipose tissue 200	
eosinophils (Fig. 2H). Compared to wild type mice, both genetically deficient 201	
animals displayed similar or increased inflammation in the adipose tissue, but the 202	
IL-10-/-/IL-4-/- mice were resistant to steatosis and NASH when placed on a HFD 203	
as measured by hepatic triglyceride levels, serum aminotransferase levels, and 204	
histological evaluations. Together, these findings suggest that there are 205	
disconnects between the mechanisms driving inflammation and metabolic 206	
dysregulation in adipose tissues and the mechanisms driving development of 207	
NAFLD.   208	
 209	
Obese IFN-g-/- mice develop accelerated NAFLD with fibrosis  210	
To elucidate the mechanism for the reduced development of NAFLD in IL-10-/-/IL-211	
4-/- mice, we performed RNA-seq analysis on whole liver tissue isolated from WT, 212	
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IL-4-/-, and IL-10-/-/IL-4-/- mice on a normal or HFD for 15 weeks.  Ingenuity 213	
pathway analysis of significantly altered genes between the genotypes on normal 214	
or high fat diet (ANOVA) identified interferon-gamma (ifng) as the most activated 215	
pathway amongst predicted upstream regulatory pathways at baseline in the IL-216	
10-/-/IL-4-/- livers (p=2.65x10^-31). This pathway was down regulated slightly in 217	
wild type animals on HFD (zscore= -1.362). In IL-4-/- mice, the IFN-g pathway was 218	
down regulated whether the mice were on a normal diet (zscore= -3.805) or HFD 219	
(zscore= -2.64). In contrast, the IFN-g pathway was the highest predicted 220	
upregulated pathway in IL-10-/-/IL-4-/- mice on normal diet (zscore= 7.678), and 221	
was only slightly reduced when the mice were fed the HFD (zscore= -1.069) (Fig. 222	
3A.). The IFN-g signature in IL-10-/-/IL-4-/- mice was further validated when we 223	
searched for genes that, according to their annotation, are positively linked with 224	
IFN-g activity (Fig. 3A, heatmap). These data suggest that elevated baseline 225	
hepatic levels of IFN-g that are highly activated in the IL-10-/-/IL-4-/-, but not in IL-226	
4-/- mice, may be protective against NAFLD.   227	
Since the IFN-g pathway was such a strong predictor of resistance or 228	
susceptibility to NAFLD in the IL-4 and IL-10/IL-4 genetically deficient mice, we 229	
investigated if IFN-g plays an important regulatory role in the progression of 230	
NAFLD. IFN-g-/- mice on HFD for 15 weeks had similar increases in body weight 231	
and fat mass as wild type mice (Fig. 3B). However, the IFN-g-/- mice displayed 232	
dramatically increased hepatomegaly, and significantly increased steatosis 233	
compared to wild type animals when assessed by liver triglyceride content and oil 234	
red O staining (Fig. 3B and C). In additional studies, we found increased NAFLD 235	
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in IL-12-/- and IL10-/-/IL-12-/- mice compared to WT mice, but no differences in 236	
NAFLD between IL-12-/- and IL-10-/-/12-/- mice, suggesting that increased 237	
presence of type-1 regulatory mechanisms driven by IL-12 and IFN-gamma are 238	
ultimately responsible for the differences we observed in the IL-10-/-/4-/- mice 239	
rather than a specific effect of IL-10 (Supplemental Fig. 5). We also observed 240	
areas of NASH-like fibrotic deposition in the IFN-g-/- mice by picrosirius red 241	
staining, which were undetectable in wild type livers at the early 15-week time 242	
point (Fig. 3C, bottom panels). Additionally, the IFN-g-/- mice had evidence of 243	
increased liver damage as measured by serum ALT (Fig. 3D). The early 244	
detection of fibrosis in IFN-g-/- mice was also accompanied by increased 245	
expression of collagen 3a1, alpha smooth muscle actin and extracellular matrix-246	
associated protein periostin, which is produced by activated myofibroblasts in 247	
response to TGF-b1 and IL-13 stimulation (Fig. 3D) (26, 27). Given that 248	
progression to fibrosis was accelerated in obese IFN-g-/- mice, we also examined 249	
whether TGF-b1 activity was altered. Indeed, expression of TGF-b1 was 250	
significantly increased in the livers of IFN-g-/- mice, as were TIMP-1 and MMP-2, 251	
which are both regulated by activated TGF-b1 (Fig. 3E) (28, 29). Furthermore, 252	
we observed localization of nuclear phosphorylated-Smad3 in a greater 253	
frequency and variety of cell types present in the livers of HFD challenged IFN-g-/- 254	
mice (Fig. 3F). 255	
 256	
Next, we analyzed adipose tissues for markers of inflammation and detected 257	
increased tnf and ccl2 expression in the obese IFN-g-/- mice and a substantial 258	
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decrease in the number of tissue eosinophils (Supplemental Fig. 6A). 259	
Nevertheless, despite these changes, we failed to detect any significant increase 260	
in gross histological inflammation in the adipose tissues of IFN-g-/-, which 261	
contrasts with the findings obtained in the adipose tissues of obese IL-4-/- mice 262	
(Supplemental Fig. 6B). The worsening NASH-associated fibrosis is likely 263	
explained in part by the increased TGF-b1 signature in the livers of IFN-g-/- mice 264	
relative to wild-type or IL-4-/- mice, as well as the increased expression of TGF-b1 265	
in adipose tissues (Supplemental Fig. 6C).  266	
 267	
NASH-driven fibrosis is partly TGF-b-dependent   268	
Although TGF-b activity has been documented in the livers of NAFLD/NASH 269	
patients and in animal models of NAFLD/NASH, and proposed as a therapeutic 270	
target, detailed experimental manipulation of the pathway to determine its 271	
importance in NASH-associated fibrosis and immune activation has not been 272	
performed (30-33). Thus, to determine the role for TGF-b signaling in chronic 273	
HFD-induced NASH, and to validate its potential as a therapeutic target in NASH, 274	
we placed WT mice on a HFD for 40 weeks and TGF-b activity was inhibited 275	
therapeutically during the final four weeks of the study. Compared to animals 276	
receiving control antibody injections, the animals treated with a pan TGF-b 277	
blocking antibody did not display significant differences in body composition, 278	
hepatomegaly, or steatosis as measured by liver triglycerides (Fig. 4A and B). 279	
When we analyzed histological fibrosis using picrosirius red staining, there was a 280	
modest yet significant decrease in characteristic NASH fibrosis quantified as 281	
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fibrotic fraction in the mice receiving anti-TGF-b therapy after just 4 weeks (Fig. 282	
4B). This was also associated with a decrease in expression of pro-collagen3a1 283	
and pro-collagen1a1. However, TGF-b antibody blockade did not affect periostin 284	
or pro-collagen6a1 mRNA expression (Fig. 4C.). Periostin has been proposed as 285	
a biomarker of type-2 inflammation in asthma (34), and we have similarly 286	
identified pro-collagen6a1 as a marker of IL-13-dependent inflammation and 287	
fibrosis (35). Thus, we hypothesized that type-2 inflammation was likely 288	
contributing to the persistent expression of these pro-fibrotic biomarkers in the 289	
anti-TGF-b treated mice. Therefore, to investigate whether TGF-b blockade was 290	
having any impact on immune homeostasis, we analyzed the cytokine response 291	
in re-stimulated CD4+ T cells isolated from the liver. Production of IFN-g was 292	
largely unaffected by the chronic HFD or by antibody treatment. However, 293	
production of IL-4 by T cells was markedly increased in the mice treated with 294	
anti-TGF-b mAb (Fig 4D). We also noted a modest increase in IL-13 production 295	
in the control Ab treated mice fed a HFD (Fig. 4E.). We also observed increased 296	
expression of chi3l3, an inducible marker of type-2 immunity, in the HFD group, 297	
which was further augmented by anti-TGF-b therapy (Fig. 4E). Collectively, these 298	
data revealed the presence of low level type-2 cytokine-associated inflammation 299	
in livers of mice with progressive NAFLD, which was further exacerbated by 300	
TGF-b blockade. Therefore, emergence of compensatory pro-fibrotic type-2-301	
cytokine response could impair the efficacy of TGF-b pathway inhibitors in 302	
NAFLD-associated fibrosis.  303	
 304	
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Accelerated NASH-driven fibrogenesis in obese IFN-g-/- mice is 305	
characterized by eosinophilic inflammation during TGF-b blockade  306	
We repeated the TGF-b blockade studies in both wild type and IFN-g-/- mice on a 307	
HFD for 20 weeks to test if the highly susceptible IFN-g-/- mice would serve as a 308	
more rapid model of NASH and to further investigate the potential involvement of 309	
type-2 immunity in the progression of NAFLD. Once again IFN-g-/- mice 310	
developed severe hepatomegaly by 20 weeks, which contrasted with WT mice 311	
that displayed little evidence of advanced NAFLD at this time point. Despite 312	
variability in histological fibrosis at this time point assessed by picrosirius red 313	
staining (Fig. 5A), we detected significant increases in pro-collagen3a1 and pro-314	
collagen6a1 mRNA expression in the IFN-g-/- mice and modest increases in 315	
periostin expression in mice treated with anti-TGF-b mAbs, confirming the 316	
machinery driving fibrosis was substantially increased (Fig. 5B). Since IFN-g is 317	
known to cross-regulate type-2 inflammation, we hypothesized that the increases 318	
in periostin and pro-collagen6a1 expression could be due to a further 319	
dysregulation of cytokine responses in the livers of these mice, which was 320	
validated by increases in IL-13 mRNA expression observed in both wild-type and 321	
IFN-g-/- mice following TGF-b blockade (Fig. 5C.).   322	
 323	
To determine the functional impact of the enhanced type-2 response on the liver 324	
microenvironment, we examined ccl11 expression and quantified tissue 325	
eosinophils, which have been shown to promote inflammation and fibrosis. Both 326	
were increased in the livers of IFN-g-/- mice and further exacerbated by TGF-327	
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b blockade (Fig. 5C and D), but we were surprised to find a similar but less 328	
dramatic increase in eosinophils in WT mice as well, despite the fact that ccl11 329	
expression was not increased in this group. This increase in eosinophils with 330	
TGF-b blockade was recapitulated in 40 week treated wild type mice 331	
(Supplemental Fig. 7A). The presence of tissue eosinophils was confirmed 332	
through histological analysis of Giemsa stained liver sections (Fig. 5E) and 333	
immunofluorescent imaging of siglec-F+ leukocytes in liver tissue (Fig. 5F). Few if 334	
any eosinophils were observed in WT or IFN-g-/- mice fed a normal diet, with 335	
occasional eosinophils found in microgranulomas. In contrast, eosinophils were 336	
scattered throughout the liver sinusoids in the HFD mice. They were also 337	
localized in areas of marked lobular inflammation and macrosteatosis where 338	
fibrosis is observed. To further validate these observations and to confirm if 339	
increases in the presence of type-2 inflammation are associated with the 340	
worsening NASH phenotype, we also assessed livers from WT animals on a 341	
chronic 40-week HFD for ccl11 expression and presence of eosinophils 342	
(Supplemental Fig. 7B), and detected significant increases in both measures. 343	
Since IFN-g negatively regulates both TGF-b and type 2 immunity, we wanted to 344	
verify that the marked protection observed in the livers of IL-10-/-/4-/- mice was not 345	
accompanied by any induction of a profibrotic type-2 response. Confirming the 346	
evidence of hepatic protection in these mice, there was almost no induction of 347	
tgfb1 or evidence of increased TGF-b or IL-13 activity measured by timp1 and 348	
postn expression or accumulation of eosinophils at 40 weeks on HFD.  In 349	
contrast, all of these measures were increased in WT mice (Supplemental Fig. 350	
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8). This demonstrates that the increased IFN-g signaling in the livers of the IL-10-351	
/-/4-/- mice is associated with protection and that activation of TGF-b or type-2 352	
inflammation requires an additional stimulus such as steatosis or hepatic 353	
damage. We also examined the livers for the presence of tissue neutrophils and 354	
expression of neutrophil elastase, which we would have predicted to increase, 355	
based on models of type-1 inflammation serving as the major driver of NASH 356	
pathogenesis. Although we observed modest increases in expression of 357	
neutrophil elastase, particularly during TGF-b blockade, we found no significant 358	
changes in the frequencies of tissue neutrophils associated with HFD alone, 359	
TGF-b blockade, absence of IFN-g or chronic HFD (Supplemental Fig. 7C and D). 360	
As such, these observations are in stark contrast to the shifts in immune balance 361	
and loss of resident eosinophils seen in obese adipose tissue, indicating a 362	
significant divergence in the pathogenic mechanisms driving disease in each 363	
organ.      364	
Finally, because of the increases in IL-13 production, upregulation of IL-13 365	
responsive genes, and increased presence of eosinophils, which both respond 366	
and contribute to IL-13 signaling, we investigated the combined roles of IL-13 367	
and TGF-b in the progression of NASH-associated fibrosis. Returning to the 40-368	
week model of NASH, we treated weight-matched animals therapeutically during 369	
the final four weeks with control, anti-TGF-b, or combined anti-TGF-b and anti-IL-370	
13. Although the treatment regimen was too short to detect meaningful changes 371	
in disease, it was clear the antibodies were blocking fibrogenesis as we observed 372	
significant decreases in expression of both col3a1 and col6a1 with the dual 373	
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blockade (Fig. 5G). This confirmed our hypothesis that col6a1 expression was 374	
being driven by IL-13 signaling since it was unaffected by the single TGF-b 375	
blockade. These observations demonstrate that TGF-b and IL-13 cooperatively 376	
drive fibrogenic pathways in the murine NASH liver.  377	
 378	
AMLN diet induced NASH recapitulates IFN-gamma regulation and type-2 379	
inflammation even with modest adipose inflammation. 380	
To determine the broad applicability of our findings in NASH, we repeated our 381	
analyses with WT and IFN-γ-/- knockout animals after 15 weeks on the AMLN 382	
diet (40% fat, 20% fructose and 2% cholesterol) (32, 43). This more severe 383	
model of NASH recapitulated our main findings, with IFN-γ-/- mice displaying 384	
similar increases in body weight (Fig. 6A), but having significantly increased 385	
hepatomegaly (Fig. 6A), expression of fibrotic markers (Fig. 6B), evidence of 386	
fibrosis (Fig. 6C), and hepatic damage (Fig. 6D). Furthermore, we found dramatic 387	
increases in induction of type-2 inflammation in both WT and IFN-γ-/- knockout 388	
animals measured by frequencies of IL-13 producing CD4 T cells and tissue 389	
expression of periostin (Fig. 6E), with significant increases in both measures in 390	
IFN-γ-/- mice. This was associated with increases in eosinophils and not 391	
neutrophils in the livers of IFN-γ-/- mice (Fig. 6F). As suggested by the reduced 392	
weights of mice on the AMLN diet, reductions of eosinophils and increases in 393	
expression of TNF-α in the adipose tissue was less marked than what was 394	
observed with mice on a HFD (Fig. 6G), suggesting the induction of type-2 395	
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inflammation and fibrosis can occur somewhat independently from immune 396	
alterations in the adipose tissue. 397	
 398	
Human NASH is characterized by type-2 eosinophilic inflammation  399	
To confirm if our NASH models were accurately recapitulating human disease 400	
and to determine if our findings would be relevant to patients and potential 401	
therapeutics, we performed an analysis of NASH biopsies and publicly available 402	
microarrays from NASH patients. Firstly, to determine if there is a component of 403	
type-2 inflammation present in NASH patients, we assessed cytokine production 404	
from isolated and expanded intrahepatic lymphocytes after anti-CD3/CD28 re-405	
stimulation. Compared to lymphocytes isolated from healthy controls, NASH 406	
associated lymphocytes produced increased amounts of IL-4, IL-5, and IL-13 407	
(Fig. 7A). Furthermore, when stratified by pathologist assigned METAVIR fibrosis 408	
scores, we observed increased type-2 cytokine production with worsening 409	
fibrosis, with significant increases observed in IL-5 and IL-4 between lower (F0-2) 410	
and higher (F3-4) fibrosis scores (Fig. 7B.). Secondly, we determined that 411	
eosinophils were present in NASH patient livers by histological analysis and 412	
observed eosinophils present in similar patterns as seen in the murine livers in 413	
every NASH biopsy analyzed (n=26) (Fig. 7C and Supplemental Figure 11).  414	
 415	
To further support eosinophils as an indicator of type-2 inflammation and 416	
potential contributor in progressive NASH, we performed an analysis of publicly 417	
available microarray data from healthy, steatotic and NASH livers for genes with 418	
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significant differential expression (36). Of the transcripts with significantly altered 419	
expression by steatosis or NASH, we identified 37 genes either annotated as or 420	
implicated in eosinophil function (37). Hierarchical clustering by samples and 421	
principal component analysis using this gene set clearly separates the NASH 422	
from the healthy control and steatotic biopsies (Fig. 7D.). Finally, we assessed 423	
potential mechanisms of eosinophil accumulation in the human microarray data. 424	
Although we did not detect significant changes in expression of the eotaxin 425	
genes in NASH microarrays, the eosinophil-associated chemoattractant genes 426	
CCL5, CCL23 and PTGDS were all significantly upregulated in NASH patients 427	
(Supplemental Fig. 9) (37-43). These data indicate a previously unappreciated 428	
role for aspects of the type-2 response as a component of the inflammatory 429	
milieu contributing to NASH in patient livers and suggest that chronic HFD, 430	
AMLN diet, and the inflammatory pathway modifications we explore here reliably 431	
replicate this aspect of progression of NAFLD.  432	
 433	
Discussion 434	
Research on the inflammation associated with NAFLD progression to NASH and 435	
cirrhosis has almost universally focused on components of the pro-inflammatory 436	
type-1 response including IL-1β, TNF-α, IL-6, IL-12 and TLR activation (16, 44). 437	
In the present study we observed type-2 inflammatory components in both 438	
mouse and human NASH, suggesting a previously unappreciated role for type-2 439	
inflammation in the progression of NASH to fibrosis, as IL-13 is a  well-known 440	
contributor to progressive end stage fibrosis in diseases of diverse etiology. The 441	
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data presented here illustrate a much more mixed inflammatory milieu in the fatty 442	
liver than current models suggest, which could have significant implications for 443	
therapeutics that are based on altering the character of the inflammatory 444	
response in patients with NASH. Even though eosinophils and other type-2 445	
associated inflammatory cells play a protective role in adipose tissues, the 446	
findings here demonstrate that dysregulated type-2 inflammation contributes to 447	
the progression of steatosis and fibrosis in the liver (Supplemental Figure 11).  448	
 We initiated these studies to better understand the protective and 449	
pathogenic roles of type-1 and type-2 inflammation in the pathogenesis of 450	
NAFLD as recent studies have suggested that type-2 immunity plays a protective 451	
role in metabolic syndrome. Although we confirmed an important counter-452	
regulatory role for type-2 cytokines in adipose tissue inflammation (11, 12, 14, 453	
15), our studies in IL-10-/-/IL-4-/- and IFN-g-deficient animals revealed an 454	
unexpected protective role for some components of type-1 inflammation in 455	
NAFLD progression. Mechanistically, we show that targets of this IFN-g 456	
regulation include the cytokines TGF-b and type-2 associated IL-13, which were 457	
dysregulated in the absence of IFN-g. TGF-b has also previously been observed 458	
in NAFLD and this pathway has been proposed as a possible therapeutic target 459	
for NASH associated fibrosis (33, 45).   460	
To directly address the contribution of TGF-β to NAFLD-associated 461	
fibrosis, we performed a series of studies in which TGF-β activity was blocked 462	
therapeutically. Although a previous study characterized hepatocyte specific 463	
deletion of Tgfbr2 in choline deficient diet induced NASH (45), our studies 464	
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represent experimental intervention of TGF-b focusing on two critical targets of 465	
TGF-b signaling, fibroblasts and immune cells, without the caveat of eliminating 466	
potentially important TGF-b signaling during liver development. We found that 467	
TGF-β blockade  alleviated profibrotic signaling pathways without having any 468	
detectable impact on average body weight, liver weight, or steatosis. However, in 469	
wild type mice, we detected no changes in col6a1 and the matrix protein 470	
periostin, which have both been linked with IL-13-dependent inflammation and 471	
fibrosis (34, 35, 46). We also observed marked increases in il4 and chi3l3 472	
expression following TGF-β blockade, but little to no change in markers of type-1 473	
inflammation, suggesting that TGF-β signaling regulates the emergence of type-2 474	
inflammation in the fatty liver. These observations were even more striking in the 475	
highly susceptible IFN-g-/- mice, in which TGF-β blockade led to marked increase 476	
in col6a1, col3a1, postn, il13, and ccl11 expression. We also observed increases 477	
in the number of eosinophils in the livers of the anti-TGF-β treated IFN-g-/- mice. 478	
Thus, although we showed TGF-β serves as a mediator of fibrosis in NASH, 479	
these studies also uncovered an important collaborative role for type-2 immunity 480	
and IL-13 specifically in the progression of NASH and fibrosis. 481	
The explanation for these findings remain unclear, although we 482	
hypothesize that activation of TGF-b and IL-13 signaling in the liver likely 483	
represents a feedback loop to repair hepatic damage induced by pro-484	
inflammatory type-1 cytokines, lipid TLR ligands, dyslipidemia, and bacterial 485	
byproduct translocation during obesity-associated dysbiosis. Persistent activation 486	
or dysregulation of these repair pathways can lead to the development of 487	
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pathological fibrosis. This is supported by our detection of increased intrahepatic 488	
lymphocyte production of IL-4, IL-13, IL-5 and eosinophil accumulation in NASH 489	
patients. Indeed, eosinophils and type-2 cytokines have been implicated in both 490	
tissue repair and regeneration in models of acute liver injury (47, 48), and also in 491	
the development of fibrosis (35, 49, 50). Thus, given the hepatic injury and 492	
hepatomegaly associated with NAFLD and our observation of eosinophils in 493	
areas of macrosteatosis and fibrosis, we hypothesize that eosinophils, which are 494	
major producers of type-2 cytokines, including IL-13 (51, 52), may initially support 495	
liver repair and regeneration to maintain liver function, and at more chronic 496	
stages may contribute to the development of fibrosis. The increasing pressure to 497	
repair the liver as obesity and metabolic syndrome become chronic may also 498	
explain the rapid loss of eosinophils from adipose tissues. Thus, worsening 499	
NAFLD could provide a feed-forward loop to further exacerbate adipose tissue 500	
dysregulation. Finally, our ability to stratify human NASH patients from normal 501	
and steatotic patients based on eosinophil related gene expression and 502	
identification of eosinophils in 100% of NASH patient biopsy histologic sections 503	
analyzed suggest that the presence of eosinophils or eosinophil-derived 504	
mediators in liver biopsies may serve as a useful indicator of advancing NASH 505	
and presence of type-2 inflammation more generally.   506	
 To directly test the contribution of type-2 associated inflammation to the 507	
activation of fibrogenic pathways in NASH, we blocked the key profibrotic 508	
cytokine IL-13 with a neutralizing monoclonal antibody in combination with anti-509	
TGFβ and found that IL-13 but not TGFβ is critically required for the activation of 510	
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col6a1 expression in the liver. Thus, IL-13 and TGFβ appear to activate distinct 511	
pro-fibrotic mechanisms during the progression of NAFLD, suggesting that dual 512	
targeting of both core pathways may be needed to ameliorate the fibrotic 513	
progression of established fatty liver disease. Dual targeting may be particularly 514	
important since we observed the most dramatic increase in type-2 immunity 515	
when TGF-β was inhibited.      516	
There are potential limitations to this study that may serve as future 517	
avenues of research or offer alternative interpretations of the data. With our use 518	
of global cytokine knockout animals, we focused on the liver and adipose tissue 519	
because these mice displayed similar susceptibility to obesity.  However, we 520	
cannot exclude the possibility that the immune alterations were not having 521	
additional systemic effects, such as altering nutrient absorption in the intestine, 522	
modifying the microbiome, or modulating hormonal and nervous system 523	
signaling.  Additionally, the number of NASH patient biopsies we assessed for 524	
intrahepatic lymphocyte cytokine production (n=14), the presence of eosinophils 525	
(n=26), and microarray analysis (n=16) was relatively small making it uncertain 526	
whether type-2 inflammation serves as a universal driver of NASH or whether it 527	
only characterizes a particular subset of patients.  However, given the similarities 528	
between the mouse and human data, and the fact that the biopsies, histological 529	
analyses, and microarray data were gathered from independent research groups, 530	
there is substantial evidence supporting a critical role for type 2 immunity in the 531	
progression of NAFLD.  Finally, although we were able to detect eosinophils in all 532	
NASH biopsies and identified transcriptional changes that were consistent with 533	
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eosinophilic inflammation, we have not yet directly quantified eosinophils in 534	
human NASH or correlated their numbers with disease severity, which will be an 535	
important goal of future research.  536	
 In summary, we have identified a mixed inflammatory setting specific to 537	
the fatty liver containing a previously unappreciated component of type-2 immune 538	
activation marked by IL-13 and eosinophils, which collaborates with TGF-β 539	
through overlapping and independent mechanisms to drive fibrosis. We found 540	
evidence of this type-2 immune activation and eosinophil accumulation in both 541	
mouse and human NASH. These studies represent a paradigm shift in 542	
inflammatory characterization of steatohepatitis and have important implications 543	
for potential therapeutic interventions aimed at NASH and the metabolic 544	
syndrome.  545	
 546	
 547	
 548	
 549	
 550	
 551	
 552	
 553	
 554	
 555	
 556	
25		
Materials and Methods 557	
Study Design.  558	
Our primary objective was to investigate the immunological contribution to NASH 559	
progression and fibrosis. To do this, we disrupted major regulatory cytokines or 560	
experimentally blocked relevant signaling molecules in diet-induced mouse 561	
models of progressive NAFLD/NASH. No statistical methods were used to 562	
predetermine sample size. Group sample size was chosen using records of 563	
variance in past experiments, and variance is similar between groups being 564	
statistically compared. All experiments were independently replicated two or 565	
more times. Samples or data points were excluded only in the case of a technical 566	
equipment or human error that caused a sample to be poorly controlled. Mice or 567	
samples were randomly assigned to experimental groups or processing orders. 568	
Group allocation was blinded for all mouse work when possible (such as 569	
administration of antibodies, sample quantification and analysis, and pathology 570	
scoring). The ARRIVE (Animal Research: Reporting of In Vivo Experiments) 571	
guidelines in the EQUATOR (Enhancing the Quality and Transparency of Health 572	
Research) Network library were followed for this report. 573	
Primary data are located in Table S1. 574	
 575	
Mice 576	
The National Institute of Allergy and Infectious Diseases Division of Intramural 577	
Research Animal Care and Use Program, as part of the National Institutes of 578	
Health Intramural Research Program, approved all of the experimental 579	
26		
procedures (protocol “LPD 16E”). The Program complies with all applicable 580	
provisions of the Animal Welfare Act 581	
(http://www.aphis.usda.gov/animal_welfare/downloads/awa/awa.pdf) and other 582	
federal statutes and regulations relating to animals. 6-8-week-old C57BL/6 male 583	
mice or knockout strains on C57BL/6 background were obtained from within the 584	
same barrier facility at Taconic Farms Inc. and thus were exposed to equivalent 585	
bacteria for microflora colonization. Mice were put on either a diet of 60% 586	
calories from lard fat diet from Harlan (TD.06414) or the AMLN diet with 40% fat, 587	
20% fructose and 2% cholesterol from Research Diets (D09100301). For 588	
therapies, 250 micrograms each of anti-TGF-β (BioXCell Clone: 1D11.16.8 589	
Catalog#: BE0057), IL-13 (Genentech Clone 262A-5-1) or control antibody 590	
(BioXCell Clone: MOPC-21 Catalog#: BE0083) were injected intraperitoneally 591	
twice weekly. Mouse body composition was assessed using 1H NMR 592	
spectroscopy (EchoMRI 3-in-1, Echo Medical Systems LTD, Houston, TX) with 593	
generous assistance of Oksana Gavrilova and the Mouse Metabolism Core at 594	
NIDDK. Mice were terminally anesthetized with sodium pentobarbital. All animals 595	
were housed under specific pathogen-free conditions at the National Institutes of 596	
Health in an American Association for the Accreditation of Laboratory Animal 597	
Care-approved facility. 598	
 599	
Immunofluorescent and Immunohistological Staining 600	
Liver tissue was snap frozen immediately after perfusion using a CoolRack M96-601	
ID freezing block on dry ice. Tissue was sectioned at 8 µm using a cryostat and 602	
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maintained at -80C until needed. Slides were removed from -80C and 603	
immediately fixed for 15 minutes using 10% neutral buffered formalin. Sections 604	
were permeabilized for 20 minutes using 0.2% Triton-X 100 PBS (PBST). 605	
Sections were then blocked with 2% BSA PBST for 30 minutes. Sections were 606	
washed 3 times with PBST for 5 minutes each. Primary antibodies were diluted in 607	
PBST 2% BSA and incubated with sections for 2 hours at RT. Sections were 608	
rinsed three times with PBST for five minutes each. Secondary antibodies were 609	
diluted in PBST 2% BSA and incubated with sections for 1 hour at RT. Sections 610	
were rinsed once with PBST for five minutes. Sections were then stained with 611	
300nM DAPI in PBST for 3 minutes. Sections were rinsed three times with PBST 612	
for five minutes each and then mounted for imaging using Fluoromount G 613	
(Southern Biotech). Primary antibodies Siglec-F (E50-2440), phospho-Smad3 614	
(EP823Y), ubiquitin (EPR8590-448), keratin8/18 (TROMA-1), smooth muscle 615	
actin. Secondary antibodies Goat anti-Rabbit TRITC –A24536; Goat anti-Rat 616	
Alexa488 –A11006, Chicken anti-rabbit Alexa488-A-21441; Chicken anti-rat 617	
Alexa647-A-21472.  For Immunohistological staining for ubiquitin and keratin 618	
8/18, frozen slides were thawed and treated as above, additional blocking of 619	
endogenous enzymes was performed (Dako enzyme block). Keratin8/18 was 620	
visualized by secondary staining with Goat anti-rat HRP (ab97057) developed 621	
with DAB substrate kit (ab64238). This was followed by ubiquitin staining 622	
visualized with Mach3 Rabbit HRP (M3R531) developed with Vina Green 623	
Chromagen (BRR807A).  624	
 625	
28		
Fibrosis Quantification 626	
Picrosirius red stained cross sections of three liver lobes from each mouse were 627	
imaged under polarized light. Fibrotic area was calculated by measuring total 628	
area of liver with presence of NASH specific collagen deposition quantified using 629	
Fiji image analysis software (ImageJ) and reported as fibrotic fraction. 630	
 631	
Hepatic Triglyceride Measurement 632	
Relative liver lipid was assessed by measuring glycerol content of hydrolyzed 633	
liver tissue as a surrogate of triglyceride accumulation(53-55). Briefly, glycerol 634	
was isolated from 50-100 mg of liver saponified by addition of ethanolic KOH (2 635	
parts EtOH: 1 part 30% KOH) overnight at 55C followed by addition of 1:1 water 636	
and EtOH. 1M MgCl2 was added to precipitate fatty acids and samples were 637	
spun down.  Cleared supernatants were assayed for glycerol content with 638	
colorimetric Free Glycerol Reagent (Sigma F6428) relative to a glycerol standard 639	
curve (Sigma G7793) and liver triglyceride content was calculated. 640	
 641	
Human NASH Cytokine Quantification 642	
Following informed consent, fresh human liver biopsy specimens were obtained 643	
from patients undergoing diagnostic liver biopsies at the Hepatology clinic of the 644	
Centre Hospitalier de l’Université de Montréal (CHUM). This study was approved 645	
by the institutional ethics committee (protocol SL09.228) and all experiments 646	
were performed in accordance with the declaration of Helsinki. Intrahepatic 647	
lymphocytes (IHL) were isolated by enzymatic digestion with collagenase type 2 648	
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(100 IU/mL) (Worthington) of the liver biopsy followed by mechanical dissociation 649	
through a 70 µm filter. IHLs were expanded for 15 days in 24-well plates with 650	
2x106 autologous irradiated (3000 rads) peripheral blood mononuclear cells 651	
(PBMCs) as feeder cells in presence of 50 IU/mL of IL-2 (R&D systems) and 1 652	
µg/mL of anti-CD3 (cloneUCHT1) (BD Biosciences, San Diego, CA). Expanded 653	
IHLs (2x106/mL) were re-stimulated for 3 days with anti-CD3/CD28 (1 µg/mL). 654	
Cytokine production was quantified, from supernatants collected at day 3 diluted 655	
1:2, by Legend plex analysis for Human Th cytokines (Biolegend, San Diego, 656	
CA) following the manufacturer’s instructions. Legend plex data were acquired on 657	
a standard LSRII instrument (BD biosciences) using FACS DIVA software 658	
version 8 and analyzed using LegendPlex software version 7 (Biolegend, San 659	
Diego, CA). 660	
 661	
Murine Gene Expression Analyses 662	
Liver and perigonadal adipose tissue was homogenized in TRIzol Reagent (Life 663	
Technologies; Grand Island, NY) with a Precellys 24 (Bertin Technologies; 664	
Montigny-le-Bretonneux, France). Total RNA was extracted with chloroform using 665	
a MagMax-96 Total RNA Isolation Kit (Qiagen), and reverse transcribed to cDNA 666	
using SuperScript II Reverse Transcriptase (Life Technologies).  Gene 667	
expression was quantified using Power SYBR Green PCR Master Mix (Applied 668	
Biosystems) by RT-PCR on an ABI Prism 7900HT Sequence Detection System 669	
(Applied Biosystems).  Gene expression is described relative to RPLP2 mRNA 670	
levels in naïve liver and perigonadal adipose tissue.	Gene(NCBI GenBank 671	
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Accession codes): Rplp2(NM_026020): forward 5’-ACGTCGCCTCTTACCTGCT-672	
3’, reverse 5’-GACCTTGTTGAGCCGATCAT-3’; Il13(NM_008355) forward 5’-673	
CCTCTGACCCTTAAGGAGCTTAT-3’, reverse 5’-CGTTGCACAGGGGAGTCT-674	
3’; ccl11(NM_011330) forward 5’-GAATCACCAACAACAGATGCAC-3’, reverse 675	
5’-ATCCTGGACCCACTTCTTCTT-3’; tnf (NM_013693) forward 5’-676	
GCCTCTTCTCATTCCTGCTTGT-3’, reverse 5’-677	
GGCCATTTGGGAACTTCTCAT-3’; ccl2(NM_009915) forward 5’-678	
AGGTGTCCCAAAGAAGCTGTA-3’, reverse 5’- ATGTCTGGACCCATTCCTTCT-679	
3’; postn(NM_015784) forward 5’- CTGGTATCAAGGTGCTATCTGC-3’, reverse 680	
5’-AATGCCCAGCGTGCCATAA3’; col1a1(NM_007742) forward 5’-681	
AACTGGACTGTCCCAACCCC-3’, reverse 5’-682	
TCCCTCGACTCCTACATCTTCTG-3’; col3a1(NM_009930) forward 5’-683	
AACCTGGTTTCTTCTCACCCTTC-3’, reverse 5’-684	
ACTCATAGGACTGACCAAGGTGG-3’; col6a1(NM_009933) forward 5’-685	
CGCCCTTCCCACTGACAA-3’, reverse 5’-GCGTTCCCTTTAAGACAGTTGAG-686	
3’; mmp2(NM_008610) forward 5’-CAAGTTCCCCGGCGATGTC-3’, reverse 5’-687	
TTCTGGTCAAGGTCACCTGTC-3’; timp1(NM_011593) forward 5’-688	
GCAACTCGGACCTGGTCATAA-3’, reverse 5’-CGGCCCGTGATGAGAAACT-3’; 689	
tgfb1(NM_011577) forward 5’-TGGAGCAACATGTGGAACTC-3’, reverse 5’-690	
GTCAGCAGCCGGTTACCA-3’; chi3l3(NM_009892) forward 5’-691	
CATGAGCAAGACTTGCGTGAC-3’, reverse 5’-GGTCCAAACTTCCATCCTCCA-692	
3’; elane(NM_015779) forward 5’-TGGAGGTCATTTCTGTGGTG-3’, reverse 5’-693	
CTGCACTGACCGGAAATTTAG-3’. 694	
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 695	
Murine RNA-Seq, NanoString, and Human NASH Microarray Analysis 696	
RNA isolated as described above was submitted to the NIAID Research 697	
Technologies Branch who performed RNA-seq.	Illumina NextSeq500 reads were 698	
aligned to the mouse mm10 genome with TopHat2 and mapped to the mouse 699	
RefSeq transcriptome (2015-0804) with the EM algorithm in Partek Flow (Build 700	
4.0.15.0702). The nCounter analysis system (NanoString Tech.) was utilized for 701	
gene expression analysis from RNA isolated from adipose tissue. 	RNA-seq data 702	
have been uploaded to the Gene Expression Omnibus 703	
(http://www.ncbi.nlm.nih.gov/geo/) with the accession number GSE95428. 704	
Previously published and publicly available human microarrays from clinically 705	
defined normal, steatotic and NASH patient’s livers were obtained from the 706	
ArrayExpress database (accession E-MEXP-3291). Subsequent analyses were 707	
performed using TM4 MeV microarray software suite. Welch’s t-tests were used 708	
to generate volcano plots (p < 0.05) from which list subsets were generated by 709	
using fold-difference cutoffs. Additional ANOVA tests were carried out between 710	
groups. Fold change values were uploaded to Ingenuity Pathway Analysis 711	
(Qiagen) to determine potential upstream regulators.    712	
 713	
Data Availability 714	
Accession codes for murine gene expression analysis provided above with 715	
primers. Mouse RNA-seq and human NASH microarray accession numbers 716	
provided above. 717	
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 718	
Statistical Analysis 719	
Prism (Version 6&7; GraphPad) was used for statistical analysis and graphing. 720	
Mann-Whitney or t-test was used to determine significant differences. Data sets 721	
were compared with a two-tailed t-test, and differences were considered 722	
significant if P values were <0.05. Where shown error bars represent standard 723	
deviation.  724	
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Figures 994	
 995	
Figure 1. NASH and fibrosis develop late in mice fed a high fat diet. 996	
Mice were maintained on normal diet (filled symbols) or a 60% kcal from fat diet 997	
(open symbols, HFD) for 15 (circles) or 40 weeks (squares). Body weights and 998	
liver weight and liver index (% of body weight) (A.) were collected (n=10-20). 999	
Characteristics of NASH were measured including isolated liver leukocyte counts 1000	
(B.) (n=9-12), serum ALT and AST (C.) (n=9-10), and steatosis by oil red O 1001	
staining (scale bars 100μm) (D.). Liver sections were stained with keratin 8/18 1002	
and ubiquitin to assess hepatocyte ballooning (E.) and H&E for hepatic 1003	
inflammation (E, inset showing example of lobular inflammation (scale bars 1004	
40μm)). Picrosirius Red staining was performed to assess fibrotic collagen 1005	
deposition (scale bars 200μm) (F.) and viewed under polarized light to enhance 1006	
visualization (Inset scale bar 200μm). Adipose inflammation was assessed from 1007	
Giemsa stained sections from 40 week animals (scale bars 150μm) (G.), crown-1008	
like structures marked with arrows, expression of tnf (H.) (n=4-5), and flow 1009	
cytometric analysis of Siglec-F positive adipose eosinophils amongst CD45 1010	
leukocytes (I.) (n=5-12). All data points represent a single mouse, representative 1011	
or pooled data from two or more independent experiments are shown. (Two-1012	
tailed T tests, N=2-10; *=P<0.05, **=P<0.01, ***=P<0.005, ****=P<0.0001) 1013	
 1014	
 1015	
Figure 2. Type-1 immunity drives metabolic disease but protects against 1016	
NAFLD. Wild type (circles), IL-4-/- (squares), and IL-10/4-/- (triangles) mice were 1017	
40		
maintained on normal (filled symbols) or HFD (open symbols) for 15 weeks. 1018	
obesity was measured by MRI body composition (A.) (n=4-6) and serum leptin 1019	
levels assessed by ELISA (B.) (n=3-7). NAFLD progression was assessed by 1020	
liver weight and indices (C.) (n=8-15), hepatic triglyceride measurement(n=8-11), 1021	
serum aminotransferase levels (D.) (n=4-17), and giemsa stained liver sections 1022	
(E.). Adipose inflammation was assessed through histological analysis of H&E 1023	
stained adipose sections (scale bars 150μm) (F.), adipose tissue expression of 1024	
tnf and ccl2 (G.) (n=3-11), and flow cytometric analysis of adipose eosinophils 1025	
(H.) (n=4-11). All data points represent a single mouse, representative or pooled 1026	
data from two or more independent experiments are shown. (Two-tailed T tests, 1027	
N=2-10; *=P<0.05, **=P<0.01, ***=P<0.005, ****=P<0.0001) 1028	
 1029	
Figure 3. Obese IFN-g-/- mice develop accelerated NAFLD with fibrosis 1030	
Activation scores of the IFN-g pathway were assessed by Ingenuity analysis of 1031	
significantly differentially expressed genes as determined by RNA-seq from 1032	
whole liver tissue from WT, IL-4-/-, and IL-10/4-/- mice  on HFD for 15 weeks(A.). 1033	
Expression of genes annotated as being involved in positive regulation of IFN-g 1034	
are shown in the heat map (A.). Wild type (circles) and IFN-g-/- (squares) mice 1035	
were maintained for 15 weeks on normal (filled symbols) or HFD (open symbols) 1036	
and assessed for obesity by MRI body composition measurement (B.) (n=3-5). 1037	
NAFLD progression was also assessed by liver weight(n=9-11), liver index, 1038	
hepatic triglyceride measurement (B.) (n=3-6), steatosis by Oil Red staining 1039	
(scale bars 100μm) (C. normal diet- left panels, HFD- right panels), Picrosirius 1040	
41		
Red staining of collagen (scale bars 125μm) (C. bottom panels) (visualized under 1041	
polarized light-inset (scale bars 125μm)), and serum ALT levels (D.) (n=5). 1042	
Expression of fibrotic markers col3a1(n=9-11), postn(n=9-11) and acta2 1043	
(standard deviation in shaded regions) (n=3-5) were assessed by qPCR (D.). 1044	
Expression of tgfb1 and TGF-β regulated genes timp1 and mmp2 were assessed 1045	
(E.) (n=9-11). Immunofluorescent staining for phosphor-smad3 (Green), 1046	
keratin8/18 (gray) and DAPI (Blue) (arrows indicating overlapping smad3 and 1047	
DAPI staining (F.). All data points represent a single mouse, representative or 1048	
pooled data from two or more independent experiments are shown. (Two-tailed T 1049	
tests, N=2-10; *=P<0.05, **=P<0.01, ***=P<0.005, ****=P<0.0001) 1050	
 1051	
Figure 4. NASH-driven fibrosis is partly TGF-b-dependent   1052	
Wild type mice were maintained for 40 weeks on normal (filled symbols) or HFD 1053	
(open symbols) and received 4 weeks of semi-weekly control Ig (squares) or anti-1054	
TGF-β (triangles) (250 μg each). Mice were assessed for obesity by MRI body 1055	
composition measurement (n=5-9) and hepatomegaly by liver weight and liver 1056	
index scores (A.) (n=5-12). Hepatic triglycerides were measured and fibrotic 1057	
fraction was calculated by measuring picrosirius red stained liver sections for 1058	
characteristic NASH associated fibrosis (B.) (n=4-12). Expression of four fibrosis 1059	
associated genes was measured (C.) (n=5-12). PMA/Ionomycin restimulated 1060	
hepatic CD4 T cell production of IFN-g, IL-4 (D.) and IL-13 (E. left panel) was 1061	
assessed by intracellular cytokine staining (n=5-10). Expression of the type-2 1062	
inflammation marker Chi3l3 was quantified from whole liver tissue (E. right panel) 1063	
42		
(n=4-11). All data points represent a single mouse, representative or pooled data 1064	
from two or more independent experiments are shown. (Two-tailed T tests, N=2-1065	
10; *=P<0.05, **=P<0.01, ***=P<0.005, ****=P<0.0001) 1066	
 1067	
Figure 5. Accelerated NASH-driven fibrogenesis in obese IFN-g-/- mice is 1068	
characterized by severe eosinophilic inflammation during TGF-b blockade  1069	
Wild type (circles) and IFN-g-/- (squares) mice were maintained for 20 weeks on 1070	
normal (filled symbols) or HFD (open symbols) and received 4 weeks of biweekly 1071	
control Ig or anti-TGF-β (250μg each). Liver weight and liver index were 1072	
determined(n=9-14) and fibrotic fraction was calculated from picrosirius red 1073	
stained liver sections (A.) (n=3-12). Expression of interstitial collagen genes (B.). 1074	
Periostin, IL-13 and CCL11 expression were quantified from whole liver 1075	
tissue(n=6-14). Hepatic eosinophils were measured by flow cytometric analysis 1076	
of Siglec-F positive cells amongst CD45 leukocytes (C.) (n=7-9). Eosinophils 1077	
were observed in hepatic tissue by Giemsa stained liver sections (scale bar 1078	
50μm) (D.) and by immunofluorescent staining of tissue sections for siglec-f 1079	
positive cells (scale bar 125μm) (E.).  Wild type mice were maintained for 40 1080	
weeks on normal (filled symbols) or HFD (open symbols) and received 4 weeks 1081	
of biweekly control Ig (circles), anti-TGF-β (squares), or combined anti-TGF-β 1082	
and IL-13 mAbs (triangles) (250μg each). Expression of col3a1 and col6a1 from 1083	
whole liver tissue were assessed by qPCR (G.) (n=3-6). All data points represent 1084	
a single mouse, representative or pooled data from two or more independent 1085	
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experiments are shown. (Two-tailed T tests, N=2-10; *=P<0.05, **=P<0.01, 1086	
***=P<0.005, ****=P<0.0001) 1087	
 1088	
Figure 6.	AMLN diet induced NASH recapitulates IFN-gamma regulation and 1089	
type-2 inflammation despite modest adipose inflammation. 1090	
Wild type (circles) and IFN-g-/- (squares) mice were maintained for 15 weeks on 1091	
normal (filled symbols) or AMLN diet (open symbols) and assessed for obesity by 1092	
body weight (A.) (n=5-8). NAFLD progression was assessed by liver weight and 1093	
liver index, (A.), expression of fibrotic markers Col3a1 and col3a1, and acta2 as 1094	
assessed by qPCR (B.) (n=5-7), Picrosirius Red and FAST green stained liver 1095	
sections from WT (top panels) and IFN-g-/- mice (Iower panels) on normal (left) 1096	
and HFD (right) (C.), and serum alkaline phosphatase, and ALT levels (D.) (n=4-1097	
8). Type-2 response was measured by intracellular staining of hepatic CD4 T 1098	
cells for IL-13 after PMA/Ionomycin stimulation(n=4-8), postn expression (E.) 1099	
(n=5-8), and flow cytometric analysis of hepatic eosinophils and neutrophils (F.) 1100	
(n=5-8). Adipose inflammation was measured by flow cytometric analysis of 1101	
eosinophils and tnfa expression (G.) (n=5-8). All data points represent a single 1102	
mouse, representative or pooled data from two or more independent experiments 1103	
are shown. (Two-tailed T tests, N=2-10; *=P<0.05, **=P<0.01, ***=P<0.005, 1104	
****=P<0.0001) 1105	
 1106	
Figure 7. Human NASH is characterized by Type-2 Eosinophilic 1107	
Inflammation  1108	
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Cytokine production from healthy (circles) (n=2) and NASH (squares- red 1109	
squares=HCV+ NASH patients) (n=14) patient liver biopsies was measured from 1110	
expanded intrahepatic lymphocytes after a CD3/CD28 re-stimulation for IL-4, IL-1111	
5, and IL-13 (A.). Combined cytokine production stratified by METAVIR fibrosis 1112	
score and representative anti-SMA histology from F0-F2 (left) and F3-F4 (right) 1113	
biopsies (B.). Eosinophils were observed in H&E stained liver biopsies from 1114	
patients (identified by arrows) (scale bar 25μm) (C.). Publicly available 1115	
microarray data from healthy, steatotic and NASH liver biopsies was analyzed for 1116	
eosinophil associated genes that demonstrated significantly altered expression, 1117	
and hierarchical clustering by samples (left heat map) and principal component 1118	
(right panel) analysis was performed based on this gene set (D.). All data points 1119	
represent a single patient.  1120	
 1121	
 1122	
 1123	
 1124	
 1125	
 1126	
 1127	
